COL·LABORA El Meu Clínic . Aquest enllaç s'obre en una nova pestanya.
Cerca
COL·LABORA El Meu Clínic . Aquest enllaç s'obre en una nova pestanya.
Fil de navegació
Oscar Reig

Oscar Reig

Servei d'Oncologia Mèdica Oncòleg

Grup de recerca

//orcid.org/0000-0001-5255-3692 0000-0001-5255-3692

Publicacions destacades

  • Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes

    Autors:
    Saumell, S; Fernández-Serrano, M; Mesa, A; López-Cadenas, F; Arenillas, L;
    (...)
    Roué, G; Calvo, X; Prosper, F; Díez-Campelo, M; Valcárcel, D.
    Referència: Leukemia & Lymphoma 2022.

  • Pathogenesis of penile squamous cell carcinoma: Molecular update and systematic review

    Autors:
    Ribera-Cortada, Inmaculada; Guerrero-Pineda, Jose; Trias, Isabel; Veloza, Luis; Garcia, Adriana;
    (...)
    Ribal, Maria J; Corral-Molina, Juan Manuel; Jares, Pedro; Ordi, Jaume; Rakislova, Natalia.
    Referència: International Journal Of Molecular Sciences 2022.

  • Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma

    Autors:
    Roldan, Fiorella L; Lozano, Juan J; Ingelmo-Torres, Mercedes; Carrasco, Raquel; Diaz, Esther;
    (...)
    Rubio, Jose; Reig, Oscar; Alcaraz, Antonio; Mengual, Lourdes; Izquierdo, Laura.
    Referència: Cancers 2021.

  • A renal cell carcinoma tumorgraft platform to advance precision medicine

    Autors:
    Elias, Roy; Tcheuyap, Vanina T; Kaushik, Akash K; Singla, Nirmish; Gao, Ming;
    (...)
    Seshagiri, Somasekar; Modrusan, Zora; Cantarel, Brandi L; Kapur, Payal; Brugarolas, James.
    Referència: Cell Reports 2021.

  • Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes

    Autors:
    Marin-Aguilera, Mercedes; Pereira, Maria V; Jimenez, Natalia; Reig, Oscar; Cuartero, Anna;
    Victoria, Ivan; Aversa, Caterina; Ferrer-Mileo, Laura; Prat, Aleix; Mellado, Begona.
    Referència: Cancers 2021.

  • Outcomes of systemic targeted therapy in recurrent RCC Renal Cell Carcinoma treated with adjuvant sunitinib

    Autors:
    de Velasco, G; Ruiz-Granados, A; Castellano, D; Reig, O; Massari, F;
    (...)
    Pandha, HS; del Muro, XG; Procopio, G; Oudard, S; Albiges, L.
    Referència: Bju International 2021.

  • Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer

    Autors:
    Jimenez, Natalia; Reig, Oscar; Montalbo, Ruth; Mila-Guasch, Maria; Nadal-Dieste, Lluis;
    (...)
    Rodriguez-Carunchio, Leonardo; Diaz, Sherley; Prat, Aleix; Marin-Aguilera, Mercedes; Mellado, Begona.
    Referència: Frontiers In Oncology 2020.

  • DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.

    Autors:
    Grande, E; Guerrero, F; Puente, J; Galante, I; Duran, I;
    (...)
    Garcia, JF; Malats, N; Prat, A; Real, FX; Castellano, DE.
    Referència: Journal Of Clinical Oncology 2020.

  • Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS)

    Autors:
    de Velasco, G; Ruiz-Granados, A; Reig, O; Massari, F; Duran, MAC;
    (...)
    del Muro, XG; Procopio, G; Oudard, S; Castellano, D; Albiges, L.
    Referència: Journal Of Clinical Oncology 2020.

  • Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience

    Autors:
    Ferrer-Mileo, Laura; Rodriguez, Adela; Gonzalez, Nuria; Orrillo, Mayra; Jimenez, Natalia;
    Marin-Aguilera, Mercedes; Rodriguez-Carunchio, Leonardo; Prat, Aleix; Mellado, Begona; Reig, Oscar.
    Referència: Journal Of Clinical Oncology 2020.

Projectes destacats

  • Perfil molecular asociado al beneficio a la inmunoterapia en pacientes con cáncer de próstata hormonosensible: Estudios traslacionales asociados al ensayo clínico PROSTRATEGY

    Investigador/a principal: Oscar Reig Torras
    Durada: 01/01/2022 - 31/12/2024

  • Remodelación del microambiente tumoral mediante la modulación del secretoma para mejorar la respuesta a la inmunoterapia en el carcinoma renal de células claras

    Durada: 01/01/2022 - 31/12/2024

  • Molecular and functional characterization of BAP1/PBRM1 double-mutant clear cell renal cell carcinoma.

    Investigador/a principal: Oscar Reig Torras
    Durada: 01/04/2019 - 01/04/2020

  • Celular plasticity and immune profile and its relationship with therapeutic response in patients with metastatic prostate cancer.

    Investigador/a principal: Jose Garcia Corbacho
    Codi: PI18/00714
    Durada: 01/01/2019 - 01/01/2021

  • Exploratory study of the role of TMPRSS2-ERG expression and associated transcriptional profile in metastatic castration-sensitive prostate cancer patients treated with hormonal therapy and taxanes

    Investigador/a principal: Oscar Reig Torras
    Durada: 01/01/2018